TLR4 and autoimmune polyendocrinopathy: Regarding the use of HCQ for the management of APS obstetric complications, anti-β2GP1 antibodies decrease trophoblastic differentiation via TLR4; this effect is re-established by HCQ, suggesting its therapeutic interest in APS pregnancies [112].